Quest Diagnostics Inc (NYSE:DGX) EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total value of $6,303,678.40. Following the sale, the executive vice president now owns 101,423 shares in the company, valued at approximately $10,008,421.64. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Quest Diagnostics Inc (NYSE:DGX) traded down $0.17 during trading hours on Thursday, reaching $99.08. The company’s stock had a trading volume of 933,452 shares, compared to its average volume of 887,767. The company has a market capitalization of $13,500.00, a price-to-earnings ratio of 20.64, a P/E/G ratio of 2.03 and a beta of 0.60. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78. Quest Diagnostics Inc has a 1-year low of $90.10 and a 1-year high of $112.96.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The company’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.37 earnings per share. equities research analysts expect that Quest Diagnostics Inc will post 5.65 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 9th will be paid a $0.45 dividend. This represents a $1.80 annualized dividend and a dividend yield of 1.82%. The ex-dividend date of this dividend is Monday, January 8th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 37.50%.

DGX has been the topic of several research analyst reports. Canaccord Genuity restated a “buy” rating and set a $118.00 target price on shares of Quest Diagnostics in a research report on Wednesday, September 13th. Raymond James Financial restated a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. ValuEngine lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Credit Suisse Group cut their target price on Quest Diagnostics from $110.00 to $99.00 and set a “neutral” rating on the stock in a research report on Thursday, September 28th. Finally, Zacks Investment Research lowered Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $106.20.

Institutional investors have recently modified their holdings of the company. WFG Advisors LP raised its stake in shares of Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock worth $107,000 after purchasing an additional 301 shares during the last quarter. Sun Life Financial INC raised its stake in shares of Quest Diagnostics by 14,142.9% in the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock worth $111,000 after purchasing an additional 990 shares during the last quarter. Acrospire Investment Management LLC raised its stake in shares of Quest Diagnostics by 300.0% in the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock worth $178,000 after purchasing an additional 1,200 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Quest Diagnostics in the second quarter worth approximately $180,000. Finally, Parametrica Management Ltd purchased a new stake in shares of Quest Diagnostics in the third quarter worth approximately $206,000. 88.84% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/j-e-davis-sells-63880-shares-of-quest-diagnostics-inc-dgx-stock/1794611.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.